CEVCP | China-EU Vaccine Industry Collaboration Platform

Product

Service

Project

Request

[BO-Product] license-out for genetically detoxified pertussis vaccine, Engineered Pseudomonas aeruginosa vaccine, OMV-based N. gonorrhoeae vaccine

Project No :BO-CN-20231103-004

Summary

A Chinese innovative biotech company provides license-out for several novel vaccines (genetically detoxified pertussis vaccine, Engineered Pseudomonas aeruginosa vaccine, OMV-based N. gonorrhoeae vaccine).

Project Description

An innovative biotech company from Shanghai, Founded in 2021, utilizes synthetic biology tools and innovative mechanisms of action to create next-generation genetically engineered bacterial vaccines. With two technology platforms and over six pipelines, this company presents a promising solution to address global vaccine challenges, specifically the problem of antimicrobial resistance (AMR). This company raised $14M seed financing and is seeking for collaborations and license-out opportunities on multiple pipelines.

Genetically detoxified pertussis vaccine

Pertussis toxin (PT) is one of the major virulence factors of Bordetella pertussis. Because of its various noxious effects, the toxin needs to be detoxified. In all currently available vaccines, detoxification is achieved by treatment with high quantity of chemical agents such as formaldehyde, glutaraldehyde or hydrogen peroxide. Although effective in detoxification, this chemical treatment alters dramatically the immunological properties of the toxin. In contrast, this vaccine uses genetically detoxified PT, which not only meets the safety criteria but also has better immunogenicity. The company have completed evaluation of this vaccine and process development at lab scale. This vaccine targets to license out.

Engineered Pseudomonas aeruginosa vaccine

This company develop the genetically engineered live-attenuated PA vaccine with our innovative mechanism of bacterial immune checkpoint. Currently, this vaccine has exhibited good safety profile and confers good protection to P. aeruginosa infections in preliminary animal studies. Co-development is welcome.

N. gonorrhoeae vaccine (OMV-based)

Gonorrhoeae is a common sexually transmitted infection caused by Neisseria gonorrhoeae (NG). Prior studies have shown that OMV-based MenB vaccines demonstrated some level of protection towards NG. We are developing OMV-based NG vaccine through the engineering of NG to reduce toxicity, increase OMV production and display universal antigens. Preliminary POC in the above-mentioned aspects has been achieved. Co-development of NG vaccine is welcome.

Contact：

Erika HAN

Tel: 086-028-85335757

Email: Erika_han@eupic.cn

Expression of Interest

submit

Already have an account? Log in

By registered, you agree to the Conference Registration Privacy Policy.

Conference Registration Privacy Policy

I. Introduction

We highly value and respect the privacy rights and information security of our participants. When you register for our conference activities, we promise to properly handle and protect your personal information in accordance with this Privacy Policy. Please read this Privacy Policy carefully before registration to ensure that you fully understand and agree with our privacy protection measures.

II. Information Collection

We will collect the personal information you provide during the registration process, including but not limited to your name, contact details, email address, work unit, etc.
We may collect your feedback opinions, behavioral data, etc., through your participation in conference activities, questionnaires, interactive sessions, and other methods.
We will use the personal information you provide to contact you, confirm registration details, send conference notifications, provide conference-related materials, etc.
We will use your feedback opinions and behavioral data to optimize conference arrangements and improve service quality.
Without your explicit consent, we will not use your personal information for other purposes, nor will we sell or provide your personal information to third parties.

Agree